AstraZeneca today announced it has completed the purchase of Sumitomo Chemical's remaining shares in AstraZeneca K.K., the company’s Japanese subsidiary.

The purchase was valued at approximately JPY10 billion ($102 million) and gives AstraZeneca control of the entire shareholding of AstraZeneca K.K.

Marc Dunoyer, chief financial officer, AstraZeneca, said: “Our decision to gain full control of AstraZeneca K.K. reinforces our focus on Japan as a key growth platform.”

Source: AstraZeneca